You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,265,216

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,265,216

Title:	Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
Abstract:	The present invention provides a transmembrane serine protease TADG-12 protein, splice variants of the TADG-12 protein and DNA fragments encoding such proteins. Also provided are vectors and host cells capable of expressing the DNAs. The present invention further provides various methods of early detection and therapies of associated ovarian and other malignancies by utilizing the DNAs and/or proteins disclosed herein.
Inventor(s):	O\'Brien; Timothy J. (Little Rock, AR)
Assignee:	The Board of Trustees of the University of Arkansas System (Little Rock, AR)
Application Number:	10/357,175
Patent Claims:	1. An isolated DNA fragment encoding a Tumor Associated Differentially-Expressed Gene-12 (TADG-12) said DNA is selected from the group consisting of: (a) an isolated DNA fragment with the sequence shown in SEQ ID NO:1 and encoding a TADG-12 protein with the amino acid sequence shown in SEQ ID NO:2; (b) an isolated DNA fragment with the sequence shown in SEQ ID NO:3 that differs from the isolated DNA fragment of (a) above due to inclusion of an intron sequence and a new stop codon and encoding a TAGD-12 protein with the amino acid sequence shown in SEQ ID NO:4; and (c) an isolated DNA fragment differing from the isolated DNA fragments of (a) and (b) above in codon sequence due to the degeneracy of the genetic code. 2. A vector comprising the DNA fragment of claim 1 and regulatory elements necessary for expressing said DNA in a cell. 3. An isolated host cell transfected with the vector of claim 2, said vector expressing a TADG-12 protein. 4. An isolated host cell of claim 3, wherein said cell is a mammalian cell.

Details for Patent 7,265,216

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2020-03-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2020-03-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2020-03-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.